Application of circFBXW4 in the preparation of drugs for the treatment of stroke
By inhibiting the aggregation of FUS through circFBXW4 and regulating the expression of HECTD1 and IQGAP1, the problem of astrocyte activation was solved, achieving the effects of reducing the volume of cerebral infarction and restoring neurological function, providing dual application value for the treatment and diagnosis of stroke.
CN122297507APending Publication Date: 2026-06-30SOUTHEAST UNIV
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SOUTHEAST UNIV
- Filing Date
- 2026-05-25
- Publication Date
- 2026-06-30
Smart Images
Figure CN122297507A_ABST
Abstract
This invention discloses the application of circFBXW4 in the preparation of drugs for treating stroke. circFBXW4 inhibits FUS aggregation after ischemic stroke by binding to and adsorbing fibrinogen (FUS), increasing the free form of FUS, thereby upregulating the expression of downstream target protein HECTD1 and its ubiquitinated substrate IQGAP1, and subsequently inhibiting astrocyte activation. This invention systematically elucidates for the first time the mechanism of action of circFBXW4 in stroke, and makes circFBXW4 a promising candidate as a novel biomarker and molecular therapeutic target for the clinical treatment of acute ischemic stroke.
Need to check novelty before this filing date? Find Prior Art